Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1431)	4/29/2002 5:09:51 PM
From: quidditch	Respond to of 1477

OT/Related: From GS this afternoon on ABT and D2E7: <Abbott Laboratories [ABT] $54.12 ABT(RL): Positive D2E7 data enhance our confidence in $1B+ potential EPS (FY Dec): 2002E US$2.25, 2003E US$2.53 - Recommended List * We continue to recommend purchase of Abbott shares. This morning, data from several studies of D2E7, including the first ever look at Phase III results, were posted to the EULAR website. Overall, the data look positive, demonstrating that D2E7 is safe and highly effective in treating rheumatoid arthritis both as a monotherapy and in combination with other DMARDs and in both weekly and every other week dosing regimens. Moreover, the positive effects of D2E7 appear to be sustained over 2-2.5 years. These results enhance our confidence in our $1 billion+ peak sales projections for D2E7 and we continue to expect FDA approval around mid-2003. We would buy the shares at current levels. * We are maintaining our 2002 and 2003 EPS estimates of $2.25 (+20%) and $2.53 (+12%), respectively.> quid